Stevanato Group S.p.A. (STVN)
USD 22.47
(-5.07%)
USD 22.47
(-5.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 145.63 Million EUR | 1.95% |
| 2022 | 142.84 Million EUR | 6.35% |
| 2021 | 134.32 Million EUR | 71.08% |
| 2020 | 78.51 Million EUR | 100.28% |
| 2019 | 39.2 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 18.81 Million EUR | -58.4% |
| 2024 Q2 | 20.62 Million EUR | 9.63% |
| 2023 Q1 | 28.26 Million EUR | -41.58% |
| 2023 FY | 145.63 Million EUR | 1.95% |
| 2023 Q4 | 45.23 Million EUR | 19.36% |
| 2023 Q3 | 37.89 Million EUR | 10.67% |
| 2023 Q2 | 34.24 Million EUR | 21.14% |
| 2022 Q2 | 30.53 Million EUR | 10.13% |
| 2022 Q1 | 27.72 Million EUR | -37.84% |
| 2022 FY | 142.84 Million EUR | 6.35% |
| 2022 Q4 | 48.38 Million EUR | 33.59% |
| 2022 Q3 | 36.21 Million EUR | 18.62% |
| 2021 Q1 | 36.55 Million EUR | 8.14% |
| 2021 FY | 134.32 Million EUR | 71.08% |
| 2021 Q4 | 44.6 Million EUR | 139.08% |
| 2021 Q3 | 18.65 Million EUR | -45.84% |
| 2021 Q2 | 34.44 Million EUR | -5.77% |
| 2020 Q4 | 33.8 Million EUR | 103.38% |
| 2020 FY | 78.51 Million EUR | 100.28% |
| 2020 Q3 | 16.62 Million EUR | -19.97% |
| 2020 Q2 | 20.76 Million EUR | 183.51% |
| 2020 Q1 | 7.32 Million EUR | 0.0% |
| 2019 FY | 39.2 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alcon Inc. | 974 Million USD | 85.048% |
| AptarGroup, Inc. | 284.48 Million USD | 48.809% |
| Baxter International Inc. | 2.65 Billion USD | 94.517% |
| Becton, Dickinson and Company | 1.72 Billion USD | 91.563% |
| Bausch + Lomb Corporation | -260 Million USD | 156.012% |
| Haemonetics Corporation | 117.55 Million USD | -23.88% |
| Envista Holdings Corp | -100.2 Million USD | 245.34% |
| ResMed Inc. | 1.02 Billion USD | 85.736% |
| Teleflex Incorporated | 356.32 Million USD | 59.13% |
| Warby Parker Inc. | -63.19 Million USD | 330.44% |
| West Pharmaceutical Services, Inc. | 593.4 Million USD | 75.458% |